Xlife Sciences AG (FRA:XLS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XLS Xlife Sciences AG FRA:XLS
52 GF Score
Price €19.20
GF Value €7.63
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:XLS
52GF Score
Xlife Sciences AG FRA:XLS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of €19.20 is trading 151.6% above its estimated GF Value™ of €7.63. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for FRA:XLS:

  • Dividends Received:
  • GF Value™: €7.63 vs. price of €19.20 (151.6% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Switzerland
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score

Get the complete analysis for FRA:XLS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.20
Price
€7.63
GF Value